Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Ilaria S. Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A. Saunders, Randall Grose, Chung H. Kok, Jane James, Molly Tolland, Jodi A. Braley, Haley K. Altamura, David T. Yeung, Susan Branford, Agnes S. M. Yong, Timothy P. Hughes, David M. Ross

Blood (2023) 142 (25): 2192–2197.

https://doi.org/10.1182/blood.2023021119

Published: 2023

Includes: Supplemental data

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Maha M Kamel, Monika Kutyna, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2023-188340

Published: 2023

Journal Articles

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Susan Branford, Carol Wadham, Naranie Shanmuganathan, Adelina Fernandes, Nur Hezrin Shahrin, Jinghua Feng, John Toubia, Paul Wang, Chung Hoow Kok, Muneeza Maqsood, Verity Saunders, Rob King, Ming Lin, Rosalie Kenyon, Ilaria Stefania Pagani, David T Yeung, David M. Ross, Agnes S. M. Yong, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 447.

https://doi.org/10.1182/blood-2023-174425

Published: 2023

Journal Articles

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Monika Kutyna, Maha M Kamel, David M. Ross, Agnes S. M. Yong, Chun Yew Fong, Chloe Thompson-Peach, Steven W. Lane, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2023-179706

Published: 2023

Journal Articles

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Devendra Hiwase, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2023-179688

Published: 2023

Journal Articles

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Naranie Shanmuganathan, Ilaria S. Pagani, David M. Ross, Sahee Park, Agnes S. M. Yong, Jodi A. Braley, Haley K. Altamura, Devendra K. Hiwase, David T. Yeung, Dong-Wook Kim, Susan Branford, Timothy P. Hughes

Blood (2021) 137 (9): 1196–1207.

https://doi.org/10.1182/blood.2020005514

Published: 2021

Includes: Supplemental data

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

Naranie Shanmuganathan, Jodi A. Braley, Agnes S. M. Yong, Devendra K. Hiwase, David T. Yeung, David M. Ross, Timothy P. Hughes, Susan Branford

Blood (2019) 134 (1): 85–89.

https://doi.org/10.1182/blood.2019000120

Published: 2019

Includes: Supplemental data

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Blood (2018) 132 (Supplement 1): 459.

https://doi.org/10.1182/blood-2018-99-110569

Published: 2018

Journal Articles

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

Chung Hoow Kok, PhD BSc, Sakrapee Paisitkriangkrai, PhD, David T Yeung, PhD BSc, FRACP, FRCPA MBBS, Liu Liu, PhD BSc, Verity A Saunders, Phuong Dang, Agnes S. M. Yong, MD PhD, Deborah L White, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2018-99-117633

Published: 2018

Journal Articles

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, Agnes S. M. Yong, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, David M Ross, Timothy P. Hughes, MD

Blood (2018) 132 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2018-99-111083

Published: 2018

Journal Articles

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Blood (2018) 132 (9): 948–961.

https://doi.org/10.1182/blood-2018-02-832253

Published: 2018

Includes: Supplemental data

Journal Articles

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Blood (2017) 130 (Supplement 1): 251.

https://doi.org/10.1182/blood.V130.Suppl_1.251.251

Published: 2017

Journal Articles

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Emily Blyth, Barbara Withers, Leighton Edward Clancy, PhD, Agnes S. M. Yong, MDPhD, Christopher Fraser, MD, Jane Burgess, Renee Simms, Gloria Castellano Gonzalez, PhD, David Kliman, MBBS, Ming-Celine Dubosq, MD, David Bishop, Gaurav Sutrave, MBBS,, Chun Kei Kris Ma, PhDMBBS, Peter J. Shaw, MA,FRACP, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1919.

https://doi.org/10.1182/blood.V130.Suppl_1.1919.1919

Published: 2017

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Amy Hughes, PhD, Jade Clarson, Deborah L White, PhD FFSc (RCPA), David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Agnes S. M. Yong, MDPhD

Blood (2017) 130 (Supplement 1): 1581.

https://doi.org/10.1182/blood.V130.Suppl_1.1581.1581

Published: 2017

Journal Articles

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Agnes S. M. Yong, MDPhD, David M Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1621.

https://doi.org/10.1182/blood.V130.Suppl_1.1621.1621

Published: 2017

NARROW

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

3rd Party CMV-Specific T Cells Provide Long Term Protection Against Episodes of Recurrent CMV after Allogeneic Stem Cell Transplant Despite Lack of Persistence in Peripheral Blood

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only